Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2023 7
2024 3
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis.
Jiao R, Lin C, Cai X, Wang J, Wang Y, Lv F, Yang W, Ji L. Jiao R, et al. Diabetes Obes Metab. 2025 Jan;27(1):259-267. doi: 10.1111/dom.16012. Epub 2024 Oct 21. Diabetes Obes Metab. 2025. PMID: 39431379
The use of a glucagon-like peptide 1 (GLP-1) receptor-based agonist could lead to weight reduction, which might result from the loss of both fat and skeletal muscle. However, the body composition-modifying effe …
The use of a glucagon-like peptide 1 (GLP-1) receptor-based agonist could lead to weight re …
Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis.
Dutta D, Nagendra L, Joshi A, Krishnasamy S, Sharma M, Parajuli N. Dutta D, et al. Obes Surg. 2024 May;34(5):1653-1664. doi: 10.1007/s11695-024-07175-8. Epub 2024 Mar 19. Obes Surg. 2024. PMID: 38502519
BACKGROUND: A significant number of patients face the issue of weight gain (WG) or inadequate weight loss (IWL) post-bariatric surgery for obesity. Several studies have been published evaluating the role of glucagon-like peptide-1 recepto …
BACKGROUND: A significant number of patients face the issue of weight gain (WG) or inadequate weight loss (IWL) post-bariatric …
Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study.
Volpe S, Lisco G, Fanelli M, Racaniello D, Colaianni V, Lavarra V, Triggiani D, Crudele L, Triggiani V, Sabbà C, De Pergola G, Piazzolla G. Volpe S, et al. Front Endocrinol (Lausanne). 2023 Sep 13;14:1240263. doi: 10.3389/fendo.2023.1240263. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37780624 Free PMC article.
BACKGROUND: Oral semaglutide is the first glucagon-like peptide-1 receptor agonist (GLP-1RA) designed for oral administration; it offers a promising opportunity to facilitate an early approach to Type 2 Diabetes (T2D). ...At each time point, body …
BACKGROUND: Oral semaglutide is the first glucagon-like peptide-1 receptor agonist (GLP-1RA) designed for oral a …
Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial.
Cortes TM, Vasquez L, Serra MC, Robbins R, Stepanenko A, Brown K, Barrus H, Campos A, Espinoza SE, Musi N. Cortes TM, et al. JMIR Res Protoc. 2024 Sep 13;13:e62667. doi: 10.2196/62667. JMIR Res Protoc. 2024. PMID: 39269759 Free PMC article.
Semaglutide is a glucagon-like peptide 1 receptor agonist that has been approved for T2DM and chronic weight management. ...Our primary outcomes include changes in lean mass, physical function, and biomarkers of aging. Body comp …
Semaglutide is a glucagon-like peptide 1 receptor agonist that has been approved for T2DM and chronic weight …
Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans.
Langer HT, Gilmore NK, Hayden CMT, Roux J, Bariohay B, Rouquet T, Awada M, Marcotorchino J, Bournot L, Nunn E, Titchenell PM, Liskiewicz D, Müller TD, Anyiam O, Atherton PJ, Idris I, Hentschel A, Roos A, Haritonow N, Norman K, Müller-Werdan U, Baar K. Langer HT, et al. Cell Rep Med. 2026 Mar 17;7(3):102665. doi: 10.1016/j.xcrm.2026.102665. Cell Rep Med. 2026. PMID: 41850248 Free PMC article.
The large decrease in body weight with glucagon-like peptide-1 (GLP-1) medicines raises concern about a loss of lean body mass (LBM) and skeletal muscle. ...Overall, in middle-aged mice and men, GLP …
The large decrease in body weight with glucagon-like peptide-1 (GLP-1) medicines rai …
Weight loss and body composition after compounded semaglutide treatment in a real world setting.
Chun E, Siojo A, Rivera D, Reyna K, Legere H, Joseph R, Pojednic R. Chun E, et al. Diabetes Obes Metab. 2025 Mar;27(3):1536-1543. doi: 10.1111/dom.16162. Epub 2025 Jan 7. Diabetes Obes Metab. 2025. PMID: 39776038
Once-weekly semaglutide/cyanocobalamin injected subcutaneously starting at 0.25 mg/0.125 mg and titrated to a maximum dose of 2.4 mg/0.24 mg. The primary endpoint was weight loss at 3 months, with secondary analyses including weight loss percentage, weight lo …
Once-weekly semaglutide/cyanocobalamin injected subcutaneously starting at 0.25 mg/0.125 mg and titrated to a maximum dose of 2.4 mg/0.24 mg …
Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes.
Uchiyama S, Sada Y, Mihara S, Sasaki Y, Sone M, Tanaka Y. Uchiyama S, et al. J Clin Med Res. 2023 Jul;15(7):377-383. doi: 10.14740/jocmr4987. Epub 2023 Jul 31. J Clin Med Res. 2023. PMID: 37575352 Free PMC article.
Therefore, it is preferable to predominantly reduce fat without significant loss of muscle with weight loss in patients with type 2 diabetes. Previously, the anti-diabetic agent glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglu …
Therefore, it is preferable to predominantly reduce fat without significant loss of muscle with weight loss in patients with t …
[Obesity and type 2 diabetes (Update 2023)].
Clodi M, Toplak H, Resl M, Brix J, Leitner DR, Harreiter J, Hoppichler F, Wascher TC, Schindler K, Ludvik B. Clodi M, et al. Wien Klin Wochenschr. 2023 Jan;135(Suppl 1):91-97. doi: 10.1007/s00508-023-02184-6. Epub 2023 Apr 20. Wien Klin Wochenschr. 2023. PMID: 37101029 Free PMC article. German.
The body mass index (BMI) is a very crude measure of body fatness in individuals. Even normal weight persons can have too much body fat in cases of a lack of muscle mass (sarcopenia), which is why additional measurements of waist c …
The body mass index (BMI) is a very crude measure of body fatness in individuals. Even normal weight persons can …
Metabolic Impact of Frailty Changes Diabetes Trajectory.
Sinclair AJ, Abdelhafiz AH. Sinclair AJ, et al. Metabolites. 2023 Feb 16;13(2):295. doi: 10.3390/metabo13020295. Metabolites. 2023. PMID: 36837914 Free PMC article. Review.
In older people with diabetes, frailty is a newly emerging and significant complication. Frailty induces body composition changes that influence the metabolic state and affect diabetes trajectory. ...In the sarcopenic obese phenotype, the early use of sodium-glucose …
In older people with diabetes, frailty is a newly emerging and significant complication. Frailty induces body composition chan …
Comparison of the Impact of SGLT2-Inhibitors and Exenatide on Body Fat Composition.
Agcakaya E, Mutlu HH, Erbakan A, Sargin M. Agcakaya E, et al. J Coll Physicians Surg Pak. 2023 Mar;33(3):308-313. doi: 10.29271/jcpsp.2023.03.308. J Coll Physicians Surg Pak. 2023. PMID: 36945162
OBJECTIVE: To investigate the effect of SGLT2-i and GLP-1RA as an add-on therapy to metformin on weight loss and body composition, and to compare their effects on glucose and lipid parameters. ...KEY WORDS: Type 2 diabetes mellitus, Obesity, GLP-1 …
OBJECTIVE: To investigate the effect of SGLT2-i and GLP-1RA as an add-on therapy to metformin on weight loss and body compo …
12 results